Sfoglia per Autore
The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin's disease.
1982 Martelli, Massimo Fabrizio; Velardi, A.; Rambotti, P.; Cernetti, C.; Bertotto, A.; Spinozzi, Fabrizio; Bracaglia, A. M.; Falini, Brunangelo; Davis, S.
Non-B, non-T acute lymphoblastic leukaemia terminating in malignant histiocytosis: a new case and a review of the literature.
1982 Martelli, Massimo Fabrizio; Tabilio, Antonio; Aversa, F.; Mecucci, Cristina; Spinozzi, Fabrizio; Venti, G.; Falini, Brunangelo; Rambotti, P.
Intracytoplasmic lysozyme in malignant hematologic disorders: an immunoperoxidase study.
1982 Tabilio, A; Falini, Brunangelo; Aversa, F; Zuccaccia, M; Cernetti, C; Gerli, Roberto; Rutili, D; Grignani, F; Martelli, Mf
Evolutionary conservation in various mammalian species of the human proliferation-associated epitope recognized by the Ki-67 monoclonal antibody
1989 Falini, Brunangelo; Flenghi, L; Fagioli, M; Stein, H; Schwarting, R; Riccardi, Carlo; Manocchio, I; Pileri, S; Pelicci, Pg; Lanfrancone, L.
LF61: a new monoclonal antibody directed against a trimeric molecule (150 kDa, 125 kDa, 105 kDa) associated with hairy cell leukaemia.
1990 Flenghi, L.; Spinozzi, Fabrizio; Stein, H.; Krushwitz, M.; Pileri, S.; Falini, Brunangelo
Selection of a panel of monoclonal antibodies for monitoring residual disease in peripheral blood and bone marrow of interferon-treated hairy cell leukaemia patients.
1990 Falini, Brunangelo; Pileri, Sa; Flenghi, L; Liberati, Anna Marina; Stein, H; Gerli, Roberto; Minelli, O; Martelli, Mf; Lauria, F; Poggi, S.
Response to intermediate and standard doses of IFN-beta in hairy-cell leukaemia.
1990 Liberati, Anna Marina; Fizzotti, M; Di Clemente, F; Senatore, M; Berruto, P; Falini, Brunangelo; Martelli, Mf; Grignani, F.
Gli anticorpi monoclonali nella terapia delle emopatie maligne.
1993 Falini, Brunangelo; Flenghi, L; Pasqualucci, Laura; Martelli, Maria Paola; Venturi, S; Scarpelli, N; Blass, A; Stirpe, F; Pileri, S; Martelli, Massimo Fabrizio
CHARACTERIZATION OF A NEW MONOCLONAL ANTIBODY (PG-M3) DIRECTED AGAINST THE AMINOTERMINAL PORTION OF THE PML GENE PRODUCT: IMMUNOCYTOCHEMICAL EVIDENCE FOR HIGH EXPRESSION OF PML PROTEINS ON ACTIVATED MACROPHAGES, ENDOTHELIAL CELLS, AND EPITHELIA
1995 Flenghi, L; Fagioli, M; Tomassoni, L; Pileri, S; Gambacorta, M; Pelicci, Pg; Falini, Brunangelo
Cellular localization and tissue distribution of PML proteins as defined by a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product. Preferential expression in postmitotic cells.
1995 L., Flenghi; M., Fagioli; L., Tomassoni; S., Pileri; R., Pacini; Grignani, Francesco; T., Casini; P. F., Ferrucci; Martelli, Massimo Fabrizio; P. G., Pelicci; Falini, Brunangelo
Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens.
1995 Falini, Brunangelo; S., Venturi; M., Martélli; A., Santucci; S., Pileri; E., Pescarmona; M., Giovannini; P., Mazza; Martelli, Massimo Fabrizio; Pasqualucci, Laura
High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints.
1995 Gerli, Roberto; Muscat, C; Bistoni, O; Falini, Brunangelo; Tomassini, C; Agea, E; Tognellini, R; Biagini, P; Bertotto, A.
Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
1995 Pasqualucci, Laura; M., Wasik; B. A., Teicher; L., Flenghi; A., Bolognesi; F., Stirpe; L., Polito; Falini, Brunangelo; M. E., Kadin
Immunotoxin therapy of hematological malignancies.
1995 Pasqualucci, Laura; L., Flenghi; A., Terenzi; A., Bolognesi; F., Stirpe; B., Bigerna; Falini, Brunangelo
MONOCLONAL ANTIBODIES PG-B6a AND PG-B6p RECOGNIZE, RESPECTIVELY, A HIGHLY CONSERVED AND A FORMOL-RESISTANT EPITOPE ON THE HUMAN BCL-6 PROTEIN AMINO-TERMINAL REGION.
1996 Flenghi, L; Bigerna, B; Fizzotti, N; Venturi, S; Pasqualucci, Laura; Pileri, S; Ye, Bh; Falini, Brunangelo; Pacini, R; Baroni, Cd; Pescarmona, E; Anagnostopoulos, I; Stein, H; Asdrubali, G; Martelli, Massimo Fabrizio; Pelicci, Pg; DALLA FAVERA, R; Falini, B.
DISTINCTIVE EXPRESSION PATTERN OF THE BCL-6 PROTEIN IN NODULAR LYMPHOCYTE PREDOMINANCE HODGKIN'S DISEASE.
1996 Falini, Brunangelo; Bigerna, B; Pasqualucci, Laura; Fizzotti, M; Martelli, Massimo Fabrizio; Pileri, S; Pinto, A; Carbone, A; Venturi, S; Pacini, R; Cattoretti, G; Pescarmona, E; LO COCO, F; Pelicci, Pg; Anagnostopoulos, I; DALLA FAVERA, R; Flenghi, L.
Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues.
1996 M., Gambacorta; L., Flenghi; M., Fagioli; S., Pileri; L., Leoncini; B., Bigerna; R., Pacini; L. N., Tanci; Pasqualucci, Laura; Ascani, Stefano; A., Mencarelli; A., Liso; P. G., Pelicci; Falini, Brunangelo
Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.
1996 L., Flenghi; B., Bigerna; M., Fizzotti; S., Venturi; Pasqualucci, Laura; S., Pileri; B. H., Ye; M., Gambacorta; R., Pacini; C. D., Baroni; E., Pescarmona; I., Anagnostopoulos; H., Stein; G., Asdrubali; Martelli, Massimo Fabrizio; P. G., Pelicci; R., Dalla Favera; Falini, Brunangelo
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.
1996 Falini, Brunangelo; B., Bigerna; Pasqualucci, Laura; M., Fizzotti; Martelli, Massimo Fabrizio; S., Pileri; A., Pinto; A., Carbone; S., Venturi; R., Pacini; G., Cattoretti; E., Pescarmona; F. L., Coco; P. G., Pelicci; I., Anagnastopoulos; R., Dalla Favera; L., Flenghi
Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
1996 A., Terenzi; A., Bolognesi; Pasqualucci, Laura; L., Flenghi; S., Pileri; H., Stein; M., Kadin; B., Bigerna; L., Polito; P. L., Tazzari; Martelli, Massimo Fabrizio; F., Stirpe; Falini, Brunangelo
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin's disease. | 1982 | Martelli, Massimo Fabrizio; Velardi, A.; Rambotti, P.; Cernetti, C.; Bertotto, A.; Spinozzi, Fabrizio; Bracaglia, A. M.; Falini, Brunangelo; Davis, S. | |
Non-B, non-T acute lymphoblastic leukaemia terminating in malignant histiocytosis: a new case and a review of the literature. | 1982 | Martelli, Massimo Fabrizio; Tabilio, Antonio; Aversa, F.; Mecucci, Cristina; Spinozzi, Fabrizio; Venti, G.; Falini, Brunangelo; Rambotti, P. | |
Intracytoplasmic lysozyme in malignant hematologic disorders: an immunoperoxidase study. | 1982 | Tabilio, A; Falini, Brunangelo; Aversa, F; Zuccaccia, M; Cernetti, C; Gerli, Roberto; Rutili, D; Grignani, F; Martelli, Mf | |
Evolutionary conservation in various mammalian species of the human proliferation-associated epitope recognized by the Ki-67 monoclonal antibody | 1989 | Falini, Brunangelo; Flenghi, L; Fagioli, M; Stein, H; Schwarting, R; Riccardi, Carlo; Manocchio, I; Pileri, S; Pelicci, Pg; Lanfrancone, L. | |
LF61: a new monoclonal antibody directed against a trimeric molecule (150 kDa, 125 kDa, 105 kDa) associated with hairy cell leukaemia. | 1990 | Flenghi, L.; Spinozzi, Fabrizio; Stein, H.; Krushwitz, M.; Pileri, S.; Falini, Brunangelo | |
Selection of a panel of monoclonal antibodies for monitoring residual disease in peripheral blood and bone marrow of interferon-treated hairy cell leukaemia patients. | 1990 | Falini, Brunangelo; Pileri, Sa; Flenghi, L; Liberati, Anna Marina; Stein, H; Gerli, Roberto; Minelli, O; Martelli, Mf; Lauria, F; Poggi, S. | |
Response to intermediate and standard doses of IFN-beta in hairy-cell leukaemia. | 1990 | Liberati, Anna Marina; Fizzotti, M; Di Clemente, F; Senatore, M; Berruto, P; Falini, Brunangelo; Martelli, Mf; Grignani, F. | |
Gli anticorpi monoclonali nella terapia delle emopatie maligne. | 1993 | Falini, Brunangelo; Flenghi, L; Pasqualucci, Laura; Martelli, Maria Paola; Venturi, S; Scarpelli, N; Blass, A; Stirpe, F; Pileri, S; Martelli, Massimo Fabrizio | |
CHARACTERIZATION OF A NEW MONOCLONAL ANTIBODY (PG-M3) DIRECTED AGAINST THE AMINOTERMINAL PORTION OF THE PML GENE PRODUCT: IMMUNOCYTOCHEMICAL EVIDENCE FOR HIGH EXPRESSION OF PML PROTEINS ON ACTIVATED MACROPHAGES, ENDOTHELIAL CELLS, AND EPITHELIA | 1995 | Flenghi, L; Fagioli, M; Tomassoni, L; Pileri, S; Gambacorta, M; Pelicci, Pg; Falini, Brunangelo | |
Cellular localization and tissue distribution of PML proteins as defined by a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product. Preferential expression in postmitotic cells. | 1995 | L., Flenghi; M., Fagioli; L., Tomassoni; S., Pileri; R., Pacini; Grignani, Francesco; T., Casini; P. F., Ferrucci; Martelli, Massimo Fabrizio; P. G., Pelicci; Falini, Brunangelo | |
Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. | 1995 | Falini, Brunangelo; S., Venturi; M., Martélli; A., Santucci; S., Pileri; E., Pescarmona; M., Giovannini; P., Mazza; Martelli, Massimo Fabrizio; Pasqualucci, Laura | |
High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. | 1995 | Gerli, Roberto; Muscat, C; Bistoni, O; Falini, Brunangelo; Tomassini, C; Agea, E; Tognellini, R; Biagini, P; Bertotto, A. | |
Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. | 1995 | Pasqualucci, Laura; M., Wasik; B. A., Teicher; L., Flenghi; A., Bolognesi; F., Stirpe; L., Polito; Falini, Brunangelo; M. E., Kadin | |
Immunotoxin therapy of hematological malignancies. | 1995 | Pasqualucci, Laura; L., Flenghi; A., Terenzi; A., Bolognesi; F., Stirpe; B., Bigerna; Falini, Brunangelo | |
MONOCLONAL ANTIBODIES PG-B6a AND PG-B6p RECOGNIZE, RESPECTIVELY, A HIGHLY CONSERVED AND A FORMOL-RESISTANT EPITOPE ON THE HUMAN BCL-6 PROTEIN AMINO-TERMINAL REGION. | 1996 | Flenghi, L; Bigerna, B; Fizzotti, N; Venturi, S; Pasqualucci, Laura; Pileri, S; Ye, Bh; Falini, Brunangelo; Pacini, R; Baroni, Cd; Pescarmona, E; Anagnostopoulos, I; Stein, H; Asdrubali, G; Martelli, Massimo Fabrizio; Pelicci, Pg; DALLA FAVERA, R; Falini, B. | |
DISTINCTIVE EXPRESSION PATTERN OF THE BCL-6 PROTEIN IN NODULAR LYMPHOCYTE PREDOMINANCE HODGKIN'S DISEASE. | 1996 | Falini, Brunangelo; Bigerna, B; Pasqualucci, Laura; Fizzotti, M; Martelli, Massimo Fabrizio; Pileri, S; Pinto, A; Carbone, A; Venturi, S; Pacini, R; Cattoretti, G; Pescarmona, E; LO COCO, F; Pelicci, Pg; Anagnostopoulos, I; DALLA FAVERA, R; Flenghi, L. | |
Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. | 1996 | M., Gambacorta; L., Flenghi; M., Fagioli; S., Pileri; L., Leoncini; B., Bigerna; R., Pacini; L. N., Tanci; Pasqualucci, Laura; Ascani, Stefano; A., Mencarelli; A., Liso; P. G., Pelicci; Falini, Brunangelo | |
Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. | 1996 | L., Flenghi; B., Bigerna; M., Fizzotti; S., Venturi; Pasqualucci, Laura; S., Pileri; B. H., Ye; M., Gambacorta; R., Pacini; C. D., Baroni; E., Pescarmona; I., Anagnostopoulos; H., Stein; G., Asdrubali; Martelli, Massimo Fabrizio; P. G., Pelicci; R., Dalla Favera; Falini, Brunangelo | |
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. | 1996 | Falini, Brunangelo; B., Bigerna; Pasqualucci, Laura; M., Fizzotti; Martelli, Massimo Fabrizio; S., Pileri; A., Pinto; A., Carbone; S., Venturi; R., Pacini; G., Cattoretti; E., Pescarmona; F. L., Coco; P. G., Pelicci; I., Anagnastopoulos; R., Dalla Favera; L., Flenghi | |
Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. | 1996 | A., Terenzi; A., Bolognesi; Pasqualucci, Laura; L., Flenghi; S., Pileri; H., Stein; M., Kadin; B., Bigerna; L., Polito; P. L., Tazzari; Martelli, Massimo Fabrizio; F., Stirpe; Falini, Brunangelo |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile